3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Recurrence
1
Pathologic Processes
1
Oligodendroglioma
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Glioma
1
Disease Attributes
1
Astrocytoma
1
Interventions
3-Iodobenzylguanidine
3
talquetamab
2
ibrutinib
2
zanubrutinib
1
vorasidenib
1
sugemalimab
1
revumenib
1
pomalidomide
1
loncastuximab tesirine
1
fludarabine phosphate
1
fludarabine
1
denileukin diftitox
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
Whole-Body Irradiation
1
Tacrolimus
1
Panobinostat
1
Mycophenolic Acid
1
Immunotherapy, Adoptive
1
Cytarabine
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Recurrence
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing